EU/3/09/645

Table of contents

About

On 12 June 2009, orphan designation (EU/3/09/645) was granted by the European Commission to Camurus AB, Sweden, for octreotide chloride (lipid depot solution) for the treatment of acromegaly.

The sponsorship was transferred to Novartis Europharm Limited, United Kingdom, in April 2014, then to Novartis Europharm Limited, Ireland, in May 2018 and finally back to Camurus AB, Sweden, in July 2018.

Key facts

Active substance
Octreotide chloride (lipid depot solution)
Disease / condition
Treatment of acromegaly
Date of decision
12/06/2009
Outcome
Positive
Orphan decision number
EU/3/09/645

Sponsor's contact details

Camurus AB
Ideon Science Park
Lund
SE-223 70
Sweden
Tel. + 46 46 286 46 92
E-mail: orphan@camurus.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating